Krüppel-like Factor 4 Blocks Tumor Cell Proliferation and Promotes Drug Resistance in Multiple Myeloma

Overview

Journal Haematologica

Specialty Hematology

Date 2013 Apr 16

PMID 23585530

Citations 20

Authors

Matthieu Schoenhals

Alboukadel Kassambara

Jean-Luc Veyrune

Jerome Moreaux

Hartmut Goldschmidt

Dirk Hose

Bernard Klein

Affiliations

Soon will be listed here.

Abstract

Krüppel-like factor 4 is a transcription factor with anti-proliferative effects in differentiated cells, but with the ability to reprogram adult cells into cell-cycling pluripotent cells. In cancer, Krüppel-like factor 4 acts as either an anti-oncogene or an oncogene. We analyzed Krüppel-like factor 4 gene expression in multiple myeloma using Affymetrix microarrays. We generated conditionally expressing Krüppel-like factor 4 myeloma cell lines to investigate the function of this gene in myeloma biology. Krüppel-like factor 4 gene expression is high in normal plasma cells, but reduced in primary multiple myeloma cells from two-thirds of patients. It is not expressed by any human myeloma cell line due to promoter methylation. Conditional expression of Krüppel-like factor 4 led to complete cell cycle blockade, mainly in G1 phase, with no major apoptosis. This blockade was associated with induction of p21(Cip1) and p27(Kip1) in cell lines with an intact p53 pathway, and of p27(Kip1) only in those with an impaired p53 pathway. Krüppel-like factor 4 is highly expressed in the poor prognostic MS group with t(4;14) translocation and in the good prognostic CD-1 group with t(11;14) or t(6;14). The apparent contradiction of cell cycle inhibitor Krüppel-like factor 4 expression in patients with poor prognosis could be reconciled since its expression increased the resistance of myeloma cell lines to melphalan. In conclusion, we describe for the first time that Krüppel-like factor 4 could play a critical role in controlling the cell cycle and resistance to alkylating agents in multiple myeloma cells.

Citing Articles

Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma.

Jakubikova J, Cholujova D, Beke G, Hideshima T, Klucar L, Leiba M JCI Insight. 2023; 8(3).

PMID: 36752202 PMC: 9977435. DOI: 10.1172/jci.insight.159924.

In vivo temporal resolution of acute promyelocytic leukemia progression reveals a role of in suppressing early leukemic transformation.

Mas G, Santoro F, Blanco E, Gamarra Figueroa G, Le Dily F, Frige G Genes Dev. 2022; 36(7-8):451-467.

PMID: 35450883 PMC: 9067408. DOI: 10.1101/gad.349115.121.

Characterisation of Levonorgestrel-Resistant Endometrial Cancer Cells.

Dore M, Filoche S, Danielson K, Henry C Cancer Manag Res. 2021; 13:7871-7884.

PMID: 34703309 PMC: 8523362. DOI: 10.2147/CMAR.S327381.

Evaluation of the Effect of Orlistatorlistat on Expression of OCT4, Nanog, SOX2, and KLF4 Genes in Colorectal Cancer SW40 Cell Line.

Karimabad M, Roostaei F, Mahmoodi M, Hajizadeh M Asian Pac J Cancer Prev. 2021; 22(8):2335-2341.

PMID: 34452543 PMC: 8629468. DOI: 10.31557/APJCP.2021.22.8.2335.

Krüppel-like factor 4 promotes survival and expansion in acute myeloid leukemia cells.

Lewis A, Bridges C, Punia V, Cooper A, Puppi M, Lacorazza H Oncotarget. 2021; 12(4):255-267.

PMID: 33659038 PMC: 7899553. DOI: 10.18632/oncotarget.27878.

References

Rowland B, Bernards R, Peeper D . The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol. 2005; 7(11):1074-82. DOI: 10.1038/ncb1314. View

Rebouissou C, Wijdenes J, Autissier P, Tarte K, Costes V, Liautard J . A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma. Blood. 1998; 91(12):4727-37. View

Walker B, Leone P, Jenner M, Li C, Gonzalez D, Johnson D . Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood. 2006; 108(5):1733-43. DOI: 10.1182/blood-2006-02-005496. View

Takahashi K, Yamanaka S . Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126(4):663-76. DOI: 10.1016/j.cell.2006.07.024. View

Kassambara A, Hose D, Moreaux J, Walker B, Protopopov A, Reme T . Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma. Haematologica. 2011; 97(4):622-30. PMC: 3347668. DOI: 10.3324/haematol.2011.046821. View

Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M . Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood. 2005; 107(7):2633-8. DOI: 10.1182/blood-2005-10-4084. View

Jourdan M, Caraux A, De Vos J, Fiol G, Larroque M, Cognot C . An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood. 2009; 114(25):5173-81. PMC: 2834398. DOI: 10.1182/blood-2009-07-235960. View

Good K, Tangye S . Decreased expression of Kruppel-like factors in memory B cells induces the rapid response typical of secondary antibody responses. Proc Natl Acad Sci U S A. 2007; 104(33):13420-5. PMC: 1948953. DOI: 10.1073/pnas.0703872104. View

Kee H, Kook H . Krüppel-like factor 4 mediates histone deacetylase inhibitor-induced prevention of cardiac hypertrophy. J Mol Cell Cardiol. 2009; 47(6):770-80. DOI: 10.1016/j.yjmcc.2009.08.022. View

10.

Klaewsongkram J, Yang Y, Golech S, Katz J, Kaestner K, Weng N . Krüppel-like factor 4 regulates B cell number and activation-induced B cell proliferation. J Immunol. 2007; 179(7):4679-84. PMC: 2262926. DOI: 10.4049/jimmunol.179.7.4679. View

11.

Avet-Loiseau H, Leleu X, Roussel M, Moreau P, Guerin-Charbonnel C, Caillot D . Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol. 2010; 28(30):4630-4. DOI: 10.1200/JCO.2010.28.3945. View

12.

Rowland B, Peeper D . KLF4, p21 and context-dependent opposing forces in cancer. Nat Rev Cancer. 2005; 6(1):11-23. DOI: 10.1038/nrc1780. View

13.

Pei H, Zhang L, Luo K, Qin Y, Chesi M, Fei F . MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature. 2011; 470(7332):124-8. PMC: 3064261. DOI: 10.1038/nature09658. View

14.

De Vos J, Thykjaer T, Tarte K, Ensslen M, Raynaud P, Requirand G . Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene. 2002; 21(44):6848-57. DOI: 10.1038/sj.onc.1205868. View

15.

Gu Z, De Vos J, Rebouissou C, Jourdan M, Zhang X, Rossi J . Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. Leukemia. 2000; 14(1):188-97. DOI: 10.1038/sj.leu.2401632. View

16.

Moreaux J, Klein B, Bataille R, Descamps G, Maiga S, Hose D . A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica. 2010; 96(4):574-82. PMC: 3069235. DOI: 10.3324/haematol.2010.033456. View

17.

Jowsey P, Williams F, Blain P . DNA damage responses in cells exposed to sulphur mustard. Toxicol Lett. 2011; 209(1):1-10. DOI: 10.1016/j.toxlet.2011.11.009. View

18.

Zhan F, Huang Y, Colla S, Stewart J, Hanamura I, Gupta S . The molecular classification of multiple myeloma. Blood. 2006; 108(6):2020-8. PMC: 1895543. DOI: 10.1182/blood-2005-11-013458. View

19.

Ohnishi S, Ohnami S, Laub F, Aoki K, Suzuki K, Kanai Y . Downregulation and growth inhibitory effect of epithelial-type Krüppel-like transcription factor KLF4, but not KLF5, in bladder cancer. Biochem Biophys Res Commun. 2003; 308(2):251-6. DOI: 10.1016/s0006-291x(03)01356-1. View

20.

Asangani I, Ateeq B, Cao Q, Dodson L, Pandhi M, Kunju L . Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol Cell. 2012; 49(1):80-93. PMC: 3547524. DOI: 10.1016/j.molcel.2012.10.008. View